Based on this study and the correlation of anti-CFH autoantibodies with early stage NSCLC, better outcome, and longer time to recurrence (Amornsiripanitch et al., 2010; Gottlin et al., 2022), a monoclonal anti-CFH antibody was cloned from a single peripheral B cell of a NSCLC patient. This evidence concerns the gene CFH and non-small cell lung carcinoma.